Guardant Health
Guardant Health is recorded as a service provider in 172 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 172 trials · Latest update first
Study of Elironrasib (RMC-6291), With or Without Daraxonrasib (RMC-6236), in Combination With Other Anti-Cancer Agents, in Patients With RAS G12C-Mutated Non-Small Cell Lung Cancer – Subprotocol A
Sponsor Revolution Medicines Inc.
- Start (EU)
- Latest update
- Estimated end
A First-In-Human (FIH) phase I/II open-label, multicentre, dose escalation and expansion trial of VERT-002 in patients with locally advanced or metastatic solid tumors including non-small cell lung cancer (NSCLC) harboring MET alterations.
Sponsor Pierre Fabre Medicament
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2 Open-Label, Multicenter Study of RAS(ON) inhibitors in Combination with Ivonescimab with or without Other Anti-Cancer Agents in Patients with Solid Tumors
Sponsor Revolution Medicines Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Randomized, Open-label, Platform Study Using a Master Protocol to Evaluate Novel Immunotherapy Combinations as First-Line Treatment in Participants with Recurrent/Metastatic PD-L1-Positive Squamous Cell Carcinoma of the Head and Neck
Sponsor Glaxosmithkline Research & Development Limited
- Start (EU)
- Latest update
- Estimated end
KontRASt-02: A randomized, controlled, open label, phase III study evaluating the efficacy and safety of JDQ443 versus docetaxel in previously treated subjects with locally advanced or metastatic KRAS G12C mutant non-small cell lung cancer.
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
C4221016 - A Phase 3, Randomized, Double-Blind Study of Encorafenib and Binimetinib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab in Participants with BRAF V600E/K Mutation-Positive Metastatic or Unresectable Locally Advanced Melanoma
Sponsor Pfizer Inc.
- Start (EU)
- Latest update
- Estimated end
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Sponsor Janssen Cilag International
- Start (EU)
- Latest update
- Estimated end
An Open-label, Multinational Study Assessing the Efficacy and Safety of Dato-DXd Treatment in Patients With HR-positive, HER2 IHC 0, Locally Advanced Inoperable or Metastatic Breast Cancer Refractory to Endocrine Therapy (TROPION-Breast06)
Sponsor AstraZeneca AB
- Start (EU)
- Latest update
- Estimated end
A Randomized, Open-label, Phase 3 Study of Rina-S ± Bevacizumab Versus Investigator's Choice of Platinum-Based Chemotherapy ± Bevacizumab as 2L Treatment in Participants With Recurrent Platinum-Sensitive Ovarian Cancer
Sponsor Genmab A/S
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Multicenter, Open-Label Study of Velzatinib (GSK6042981) versus Imatinib in Participants with Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST)
Sponsor Glaxosmithkline Research & Development Limited
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Cetrelimab Combination Therapy in Metastatic Non-small Cell Lung Cancer
Sponsor Janssen - Cilag International
- Start (EU)
- Latest update
- Estimated end
Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (petosemtamab) as single agent or in combination in advanced solid tumors
Sponsor Merus B.V.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Open-label, Multicenter, Randomized Trial of Trastuzumab Deruxtecan in Combination With Bevacizumab Versus Bevacizumab Monotherapy as First-line Maintenance Therapy in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01/ENGOT-ov89/GEICO144-O/GOG-3112/APGOT-OV13)
Sponsor Daiichi Sankyo Inc.
- Start (EU)
- Latest update
- Estimated end
An Interventional, Open-Label, Randomized, Multicenter, Phase 3 Study of PF-07248144 Plus Fulvestrant Compared to Investigator’s Choice of Therapy in Adult Participants with Hormone Receptor-Positive, HER2-Negative Advanced/Metastatic Breast Cancer Whose Disease Progressed After Prior CDK4/6 Inhibitor-Based Therapy
Sponsor Pfizer Inc.
- Start (EU)
- Latest update
- Estimated end
C6461014 - A Phase 2 Interventional Study of PF-08634404 in Combination with Chemotherapy in Participants with Previously Untreated Transformed Small Cell Lung Cancer
Sponsor Pfizer Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase Ib/II, open-label, safety and tolerability trial of obrixtamig in combination with ZL-1310 in patients with poorly differentiated NEC
Sponsor Boehringer Ingelheim International GmbH
- Start (EU)
- Not reported
- Latest update
- Estimated end
MK-5684-004: A Phase 3, Randomized, Open-label Study of Opevesostat Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment With One Next-generation Hormonal Agent (NHA) (OMAHA-004)
Sponsor Merck Sharp & Dohme LLC
- Start (EU)
- Latest update
- Estimated end
Open label, non-randomized, Phase 1b/2 trial investigating the safety, tolerability, and antitumor activity of S095029 (anti-NKG2A antibody) as a part of combination therapy in participants with locally advanced and unresectable or metastatic MSI-H/dMMR gastro-esophageal junction/gastric cancer
Sponsor Institut De Recherches Internationales Servier IRIS
- Start (EU)
- Latest update
- Estimated end
A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children with PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation
Sponsor Relay Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 1b/2 Open-Label, Multicenter Study of Zoldonrasib (RMC-9805) with or without Daraxonrasib (RMC-6236), in Combination with Other Anticancer Agents, in Patients with RAS G12D-Mutated Non-Small Cell Lung Cancer (NSCLC) – Subprotocol C
Sponsor Revolution Medicines Inc.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Guardant Health?
The 2026-10-09 snapshot links Guardant Health to 172 distinct CTIS trials. Recorded services include Laboratory services, ctDNA Analysis, ctDNA, ctDNA analysis, among 57 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Guardant Health?
The most frequently recorded therapeutic areas are Solid Tumor Oncology, Gastroenterology, Gynecology, Respiratory. Recorded phases include Phase 2, Phase 3, Phase 1. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Guardant Health conducted?
The linked trials record locations in 27 countries, including Spain, France, Italy, Germany, Belgium. These are trial locations, not confirmed office locations or countries where Guardant Health delivered services.
What can this page tell me about Guardant Health's trial experience?
Browse 172 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 2 recorded name variants under Guardant Health. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Guardant Health
- Guardant Health Inc.